ArticleBlood cancer journal2026

Determinants of survival after failure of frontline venetoclax plus hypomethylating agent therapy in 356 patients with newly diagnosed acute myeloid leukemia.

Mahnoor Fatima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.